Efficacy of salmeterol xinafoate in horses with recurrent airway obstruction.

Abstract

OBJECTIVE:

To determine the onset, magnitude, and duration of bronchodilation after administration of aerosolized salmeterol xinafoate in horses with recurrent airway obstruction.

DESIGN:

Randomized controlled study

ANIMALS:

6 horses with recurrent airway obstruction. Procedure Horses received aerosolized salmeterol (210 microg) or no treatment, using a crossover design. Salmeterol was administered, using a mask designed for aerosol delivery in horses. Subjective rating of airway obstruction (RAO), maximal change in pleural pressure (deltaPplmax), and pulmonary resistance (RL) were determined at baseline; 5, 15, and 30 minutes; and 1, 2, 4, 6, 8, 10, and 12 hours after administration of salmeterol and in horses that did not receive treatment.

RESULTS:

The deltaPpl and RL were improved 15 minutes through 6 hours after administration of salmeterol, compared with values obtained from horses receiving no treatment. The RAO was improved 15 minutes through 2 hours after administration of salmeterol. The maximal response to salmeterol was evident 30 to 60 minutes after administration and was characterized by a 59 + 19% decrease in deltaPpl and a 56 +/- 13% decrease in RL. The deltaPpl and RL were not different from baseline values 8 hours after salmeterol administration.

CONCLUSIONS AND CLINICAL RELEVANCE:

Duration of action of salmeterol in these horses was approximately 6 hours. Maximal bronchodilation was somewhat delayed (30 to 60 minutes), and the magnitude of response was similar to that of short-acting beta2-adrenergic agonists. Salmeterol provides moderately sustained bronchodilation in horses with recurrent airway obstruction and may be an effective drug for long-term control of this condition.

• Authors: S L Henrikson, B R Rush
• Journal: Journal of the American Veterinary Medical Association (J Am Vet Med Assoc) Vol. 218 Issue 12 Pg. 1961-5 (Jun 15 2001) ISSN: 0003-1488 [Print] United States
• PMID: 11417742 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Bronchodilator Agents
• Salmeterol Xinafoate
• Albuterol

Topics

• Administration, Inhalation
• Airway Obstruction (drug therapy, veterinary)
• Albuterol (analogs & derivatives, pharmacokinetics, pharmacology, therapeutic use)
• Animals
• Bronchodilator Agents (pharmacokinetics, pharmacology, therapeutic use)
• Cross-Over Studies
• Female
• Horse Diseases (drug therapy)
• Horses
• Lung (drug effects)
• Male
• Recurrence
• Salmeterol Xinafoate
• Treatment Outcome